{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T11:44:07Z","timestamp":1768563847731,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T00:00:00Z","timestamp":1512172800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s11060-017-2695-2","type":"journal-article","created":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T03:19:53Z","timestamp":1512184793000},"page":"67-75","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Melanoma brain metastases harboring BRAF\n            \n                V600K\n             or NRAS mutations are associated with an increased local failure rate following conventional therapy"],"prefix":"10.1007","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8172-5481","authenticated-orcid":false,"given":"Penny","family":"Fang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas S.","family":"Boehling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene J.","family":"Koay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda D.","family":"Bucheit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Jakob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen H.","family":"Settle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik P.","family":"Sulman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,2]]},"reference":[{"issue":"8","key":"2695_CR1","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","volume":"117","author":"MA Davies","year":"2011","unstructured":"Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu W-J et al (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117(8):1687\u20131696","journal-title":"Cancer"},{"issue":"7","key":"2695_CR2","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","volume":"22","author":"KM Fife","year":"2004","unstructured":"Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF et al (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol Off J Am Soc Clin Oncol 22(7):1293\u20131300","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"2695_CR3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1215\/15228517-2007-058","volume":"10","author":"JJ Raizer","year":"2008","unstructured":"Raizer JJ, Hwu W-J, Panageas KS, Wilton A, Baldwin DE, Bailey E et al (2008) Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro-Oncol 10(2):199\u2013207","journal-title":"Neuro-Oncol"},{"issue":"4","key":"2695_CR4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","volume":"30","author":"PW Sperduto","year":"2012","unstructured":"Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X et al (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol Off J Am Soc Clin Oncol 30(4):419\u2013425","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6892","key":"2695_CR5","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949\u2013954","journal-title":"Nature"},{"issue":"6","key":"2695_CR6","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/humu.20481","volume":"28","author":"T Hocker","year":"2007","unstructured":"Hocker T, Tsao H (2007) Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 28(6):578\u2013588","journal-title":"Hum Mutat"},{"issue":"20","key":"2695_CR7","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","volume":"30","author":"M Colombino","year":"2012","unstructured":"Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V et al (2012) BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol Off J Am Soc Clin Oncol 30(20):2522\u20132529","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"2695_CR8","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1755-148X.2011.00873.x","volume":"24","author":"B Devitt","year":"2011","unstructured":"Devitt B, Liu W, Salemi R, Wolfe R, Kelly J, Tzen C-Y et al (2011) Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigm Cell Melanoma Res 24(4):666\u2013672","journal-title":"Pigm Cell Melanoma Res"},{"issue":"2","key":"2695_CR9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1078-0432.CCR-10-2276","volume":"17","author":"JA Ellerhorst","year":"2011","unstructured":"Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP et al (2011) Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res Off J Am Assoc Cancer Res 17(2):229\u2013235","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"6","key":"2695_CR10","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1755-148X.2010.00778.x","volume":"23","author":"SMC Broekaert","year":"2010","unstructured":"Broekaert SMC, Roy R, Okamoto I, van den Oord J, Bauer J, Garbe C et al (2010) Genetic and morphologic features for melanoma classification. Pigm Cell Melanoma Res 23(6):763\u2013770","journal-title":"Pigm Cell Melanoma Res"},{"issue":"10","key":"2695_CR11","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","volume":"29","author":"GV Long","year":"2011","unstructured":"Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ et al (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol 29(10):1239\u20131246","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"16","key":"2695_CR12","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","volume":"118","author":"JA Jakob","year":"2012","unstructured":"Jakob JA, Bassett RL, Ng CS, Curry JL, Joseph RW, Alvarado GC et al (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118(16):4014\u20134023","journal-title":"Cancer"},{"issue":"12","key":"2695_CR13","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","volume":"18","author":"AM Menzies","year":"2012","unstructured":"Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF et al (2012) Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res Off J Am Assoc Cancer Res 18(12):3242\u20133249","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"21","key":"2695_CR14","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/cncr.28306","volume":"119","author":"AD Bucheit","year":"2013","unstructured":"Bucheit AD, Syklawer E, Jakob JA, Bassett RL, Curry JL, Gershenwald JE et al (2013) Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer 119(21):3821\u20133829","journal-title":"Cancer"},{"issue":"9829","key":"2695_CR15","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","volume":"379","author":"GS Falchook","year":"2012","unstructured":"Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP et al (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet Lond Engl 379(9829):1893\u20131901","journal-title":"Lancet Lond Engl"},{"issue":"11","key":"2695_CR16","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","volume":"13","author":"GV Long","year":"2012","unstructured":"Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB et al (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087\u20131095","journal-title":"Lancet Oncol"},{"issue":"26","key":"2695_CR17","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","volume":"31","author":"PA Ascierto","year":"2013","unstructured":"Ascierto PA, Minor D, Ribas A, Lebbe C, O\u2019Hagan A, Arya N et al (2013) Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol 31(26):3205\u20133211","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"26","key":"2695_CR18","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507\u20132516","journal-title":"N Engl J Med"},{"issue":"9839","key":"2695_CR19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet Lond Engl 380(9839):358\u2013365","journal-title":"Lancet Lond Engl"},{"issue":"11","key":"2695_CR20","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2004.11.044","volume":"22","author":"SS Agarwala","year":"2004","unstructured":"Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B et al (2004) Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol Off J Am Soc Clin Oncol 22(11):2101\u20132107","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"2695_CR21","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ijrobp.2017.03.030","volume":"98","author":"PW Sperduto","year":"2017","unstructured":"Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA et al (2017) The prognostic value of BRAF, C-KIT, and NRAS mutations in melanoma patients with brain metastases. Int J Radiat Oncol Biol Phys 98(5):1069\u20131077","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2695_CR22","first-page":"611","volume":"50","author":"R Dummer","year":"2014","unstructured":"Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L et al (2014) Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer Oxf Engl 1990 50(3):611\u2013621","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"4","key":"2695_CR23","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/cncr.28445","volume":"120","author":"MWF Azer","year":"2014","unstructured":"Azer MWF, Menzies AM, Haydu LE, Kefford RF, Long GV (2014) Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib. Cancer 120(4):530\u2013536","journal-title":"Cancer"},{"issue":"446","key":"2695_CR24","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94(446):496\u2013509","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"2695_CR25","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","volume":"40","author":"L Scrucca","year":"2007","unstructured":"Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40(4):381\u2013387","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2695_CR26","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/bmt.2009.359","volume":"45","author":"L Scrucca","year":"2010","unstructured":"Scrucca L, Santucci A, Aversa F (2010) Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 45(9):1388\u20131395","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2695_CR27","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1053\/srao.2001.26020","volume":"11","author":"HA Jones","year":"2001","unstructured":"Jones HA, Hahn SM, Bernhard E, McKenna WG (2001) Ras inhibitors and radiation therapy. Semin Radiat Oncol 11(4):328\u2013337","journal-title":"Semin Radiat Oncol"},{"issue":"5","key":"2695_CR28","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.bjc.6602018","volume":"91","author":"SL Morris","year":"2004","unstructured":"Morris SL, Low SH, A\u2019Hern RP, Eisen TG, Gore ME, Nutting CM et al (2004) A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br J Cancer 91(5):829\u2013833","journal-title":"Br J Cancer"},{"issue":"3","key":"2695_CR29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3171\/2016.2.JNS1633","volume":"126","author":"Z Xu","year":"2017","unstructured":"Xu Z, Lee C-C, Ramesh A, Mueller AC, Schlesinger D, Cohen-Inbar O et al (2017) BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases. J Neurosurg 126(3):726\u2013734","journal-title":"J Neurosurg"},{"key":"2695_CR30","doi-asserted-by":"publisher","unstructured":"Kotecha R, Miller JA, Venur VA, Mohammadi AM, Chao ST, Suh JH et al (2017) Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and\/or immune-based therapies on treatment outcome. J Neurosurg 1\u201310. \n                        https:\/\/doi.org\/10.3171\/2017.1.JNS162797","DOI":"10.3171\/2017.1.JNS162797"},{"issue":"3","key":"2695_CR31","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s11060-016-2072-6","volume":"127","author":"A Wolf","year":"2016","unstructured":"Wolf A, Zia S, Verma R, Pavlick A, Wilson M, Golfinos JG et al (2016) Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. J Neurooncol 127(3):607\u2013615","journal-title":"J Neurooncol"},{"issue":"7","key":"2695_CR32","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, Saiag P, Robert C, Grob J-J, Flaherty KT, Arance A et al (2017) Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18(7):863\u2013873","journal-title":"Lancet Oncol"},{"issue":"17","key":"2695_CR33","first-page":"6483","volume":"9","author":"K Omholt","year":"2003","unstructured":"Omholt K, Platz A, Kanter L, Ringborg U, Hansson J (2003) NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res Off J Am Assoc Cancer Res 9(17):6483\u20136488","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-017-2695-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-017-2695-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-017-2695-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T13:15:11Z","timestamp":1519218911000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-017-2695-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["2695"],"URL":"https:\/\/doi.org\/10.1007\/s11060-017-2695-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,2]]}}}